Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tracking tau and cellular responses in human iPSC-microglia from uptake to seedable secretion in extracellular vesicles

ABSTRACT: The templated spread of tau aggregates in tauopathies has been attributed to neuron-to-neuron spread, but microglia have also been implicated, in mouse studies. Here we examine in detail the uptake, processing, release and seeding of tau using human iPS-derived microglia (iMGL). We show that tau is taken up by iMGL via LRP1 and heparan sulfate proteoglycans, with a role for LRRK2 in LRP1 trafficking, and that phagocytosed fibrils can escape into the cytoplasm. Tau monomer has minimal effect on iMGL, but recombinant or brain-derived tau fibrils induce a shift towards chemokine and interferon response subtypes, alongside downregulation of homeostatic and MHC genes. Endogenous tau protein is undetectable in iMGL, and monomeric tau is digested to completion, but fibrillar tau is degraded inefficiently and becomes phosphorylated on two specific residues. Finally, undegraded tau is released, including secretion as fibrils visualised by cryo-EM within extracellular vesicles, and can seed downstream neurons

ORGANISM(S): Homo sapiens

PROVIDER: GSE291195 | GEO | 2025/08/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Chronic sleep deprivation increase Tau spread via PER2-LRP1

| PRJNA835913 | ENA

Microglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathy [snRNA-Seq]

Project description:Activation of microglia is a prominent pathological feature in tauopathies, including Alzheimer’s disease. How microglia activation contributes to tau toxicity remains largely unknown. Here we show that nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling, activated by tau, drives microglial-mediated tau propagation and toxicity. Constitutive activation of microglial NF-κB exacerbated, while inactivation diminished, tau seeding and spreading in young PS19 mice. Inhibition of NF-B activation enhanced the retention while reduced the release of internalized pathogenic tau fibrils from primary microglia and rescued microglial autophagy deficits. Remarkably, inhibition of microglial NF-κB in aged PS19 mice rescued tau-mediated learning and memory deficits, restored overall transcriptomic changes while increasing neuronal tau inclusions. Single cell RNA-seq revealed that tau-associated disease states in microglia were diminished by NF-B inactivation and further transformed by constitutive NF-B activation. Our study establishes a central role for microglial NF-B signaling in mediating tau spreading and toxicity in tauopathy.

2022-03-10 | GSE198014 | GEO

Microglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathy [bulk RNA-Seq]

2022-03-10 | GSE198013 | GEO

iTF Microglia Cell-Surface Proteomics

Project description:To elucidate the impact of Aβ pathology on microglia in Alzheimer’s disease pathogenesis, we profiled the microglia surfaceome following treatment with Aβ fibrils. Our findings reveal that Aβ-associated human microglia upregulate Glypican 4 (GPC4), a GPI-anchored heparan sulfate proteoglycan (HSPG). In a Drosophila amyloidosis model, glial GPC4 expression exacerbates motor deficits and reduces lifespan, indicating that glial GPC4 contributes to a toxic cellular program during neurodegeneration. In cell culture, GPC4 enhances microglia phagocytosis of tau aggregates, and shed GPC4 can act in trans to facilitate tau aggregate uptake and seeding in neurons. Additionally, our data demonstrate that GPC4-mediated effects are amplified in the presence of APOE. These studies offer a mechanistic framework linking Aβ and tau pathology through microglial HSPGs and APOE.

2025-09-15 | PXD060977 | Pride

Granzyme K+ CD8 T cells slow tauopathy progression by targeting microglia c

Project description:Neurodegenerative diseases trigger innate and adaptive immune responses that can either slow or accelerate disease progression. How immune cells contribute to such divergent disease outcomes is not entirely clear. Here, we sought to define beneficial immune pressure that emerged during development of tauopathies in mice and humans. Using mice that express mutant human tau in neurons, we observed that microglia slowed tauopathy development by controlling the spread of tau throughout the CNS and into the blood. However, over time microglia converted into distressed antigen presenting cells, acquired neuronal transcripts, and were targeted by resident CD8+ T cells. We detected clonally expanded CD8+ T cells in the CNS and draining lymph nodes of tauopathy mice that expressed granzyme K, but not traditional effector molecules (e.g., IFN, TNF, granzymes a/b/c), which was deposited onto the microglia they targeted. In fact, engagement of microglia by granzyme K expressing CD8+ T cells was a signature of tauopathy development in mice as well as humans with tau rich brain lesions linked to age, Alzheimer’s disease, or chronic traumatic encephalopathy. Deletion of CD8+ T cells in mice promoted the appearance of distressed microglia containing neuronal transcripts, markedly enhanced tau spread, and accelerated neurological decline. These data highlight a beneficial immune reaction involving microglia and granzyme K expressing CD8+ T cells that can slow tauopathy progression. Enhancement of this coordinated response offers the potential to improve outcomes in tauopathy patients.

2025-06-20 | GSE273757 | GEO

Granzyme K+ CD8 T cells slow tauopathy progression by targeting microglia b

2025-06-20 | GSE273753 | GEO

Granzyme K+ CD8 T cells slow tauopathy progression by targeting microglia a

2025-06-20 | GSE273752 | GEO

Non-Mutated Human Tau Stimulates Alzheimer’s Disease-Relevant Neurodegeneration in a Microglia-Dependent Manner

Project description:The accumulation of abnormal, non-mutated tau protein is a key pathological hallmark of Alzheimer’s disease (AD). Despite its strong association with disease progression, the mechanisms by which tau drives neurodegeneration in the intact brain remain poorly understood. Here, we selectively expressed non-mutated or mutated MAPT in neurons across the brain and observed neurodegeneration in the hippocampus, especially associated with non-mutated human tau. Single-nuclei RNA sequencing confirmed a selective loss of hippocampal excitatory neurons and revealed the upregulation of neurodegeneration-related pathways in the affected populations. The accumulation of phosphorylated tau was accompanied by cellular stress in neurons and reactive gliosis in multiple brain regions. Notably, the lifelong absence of microglia significantly and differentially influenced the extent of neurodegeneration in the hippocampus and thalamus. Therefore, our study established an AD-relevant tauopathy mouse model, elucidated both neuron-intrinsic and neuron-extrinsic responses, and highlighted a critical role for microglia in modulating tau-driven neurodegeneration.

2025-08-06 | GSE285945 | GEO

RNAseq analysis of primary astrocyte and microglia under Aβ40WT and Aβ42WT fibrils treatment

Project description:To investigate the influence of Aβ40WT and Aβ42WT fibrils on astrocyte and microglia, we isolated astrocyte and microglia from P2 SD rats and treated glia cells with Aβ40WT and Aβ42WT fibrils for 24 hours. We then performed gene expression profiling analysis using data obtained from RNA-seq of astrocyte and microglia treated with Aβ fibrils.

2022-08-17 | GSE211198 | GEO

Microglial APOE3 Christchurch protects neurons through suppression of ferroptosis in a human iPSC-derived Alzheimer’s disease model

Project description:Alzheimer's Disease (AD) is the most prevalent neurodegenerative disorder characterized by extracellular amyloid plaque and neuronal tangle formation. A 2019 study discovered an association between the APOE3 Christchurch (APOE3Ch) variant and delayed AD progression in a PSEN1 mutation carrier. However, whether the APOE3Ch variant is causal to the delayed onset of AD and what is the underlying mechanism remains to be explored. In this study, we established neuron-microglia cocultures and neuroimmune organoids using CRISPR/Cas9-edited isogenic APOE3 and APOE3Ch microglia derived from human induced pluripotent stem cells (hiPSCs) along with PSEN1 mutant neurons or brain organoids. We show that APOE3Ch microglia exhibit enhanced phagocytic capacity and increased Tau clearance in neuron-microglia co-cultures. Moreover, APOE3Ch microglia were able to reduce phosphorylated Tau levels in PSEN1 mutant brain organoids. We also demonstrated that APOE3Ch microglia could preserve neural network activity in co-cultured PSEN1 neurons when challenged with synaptosomes prepared from AD patient brains. RNA-seq analysis identified phagocytosis and ferroptosis among pathways of differentially expressed genes from APOE3 and APOE3Ch microglia. Subsequent validation analyses established a causal link between reduced ferroptosis and enhanced phagocytosis including Tau clearance by APOE3Ch microglia, providing mechanistic insights into the neuroprotective role of APOE3Ch microglia. These findings together demonstrate that the APOE3Ch variant plays a causal role in microglial neuroprotection which can be exploited in therapeutic development for AD.

2024-12-27 | GSE240609 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data